Navigation Links
Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
Date:9/27/2007

ernational biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options.

For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... Durham, NC (PRWEB) October 24, 2014 ... appears to overcome several pitfalls of current skin grafting ... scarring and produces hair. The method, outlined in the ... a breakthrough for treating deep skin injuries that result ... skin injury completely destroys the skin’s regenerative elements. These ...
(Date:10/25/2014)... October 24, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug delivery ... Kidron will present at FireRock Capital,s Micro-Cap Conference. ... Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am ... New York City , About ...
(Date:10/25/2014)... Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the ... the Fourth International Symposium on Thymosins in Health and ... "When thymosin beta 4 (TB4) linked with ... peritoneal cavity in a rodent model of stroke, it ... brain parenchyma (the functional tissue of the brain).   The ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... Wash., June 16, 2011 SCOLR Pharma, Inc. (OTC: ... of $1 million principal amount of its 8% Senior ... initial closing of its private offering of up to ... offer additional Debentures, up to the aggregate maximum of ...
... KNDL ), a leading, global full-service ... senior clinical development experts will present on important ... 47th Annual Meeting, June 19-23, 2011, in Chicago. ... benefits of hybrid monitoring; finding an economic balance ...
... 2011 MacuCLEAR, Inc., a specialty clinical stage pharmaceutical ... vascular disorders of the eye, announced today that Philip ... OneMedForum New York 2011 on Thursday, June 23, 2011 ... New York City.   OneMedForum will focus ...
Cached Biology Technology:SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 2SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 3Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C. 2
(Date:10/19/2014)... Improving household electricity access in India over the ... nation,s total carbon emissions growth during that time, ... journal Nature Climate Change ., "Energy access ... all aspects of life, including education, communication, and ... the study. , While increased energy access is ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... found a way of stimulating the immune systems ... the devastating plaques,that are characteristic of Alzheimer's disease.,For ... a,protein-based vaccine to slow the progression of the ... created a gene-based,vaccine aimed at stimulating the immune ...
... cells',responsible for hearing and balance. Traditionally viewed as ... for the normal development,of nerve cells responsible for ... research. The study is reported in the January ... scientists at the University,of Washington.,"Using zebrafish as a ...
... essential for 'hair cells',responsible for hearing and balance. ... may be essential for the normal development,of nerve ... new,University of Utah research. The study is reported ... is co-authored by scientists at the University,of Washington.,"Using ...
Cached Biology News:Gene vaccine for Alzheimer's disease shows promising results 2GenMAPP 2.0 released 2Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined 2
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... macroporous polystyrene beads for hydrophobic interaction chromatography. ... adsorbing organics of molecular weight less than ... useful for the adsorption of nonpolar substances ... removal of detergents such as Triton X-100 ...
... : Fusion protein corresponding to ... human Mi-2 Formulation: 0.7M Tris-glycine, ... sodium azide, containing 30% glycerol ... immunoblot on Hela nuclear extract ...
... Phospho-Specific(Thr 222 ) ... 10 mM sodium HEPES, 100 ... 7.5. Recognizes the ~47 kDa ... (MAPKAPK-2) protein phosphorylated at Thr ...
Biology Products: